Antihemophilic Factor (Recombinant)

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire, Takeda

Conditions

Von Willebrand Disease

Phase 3

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

CompletedNCT02932618

Baxalta now part of ShireVon Willebrand Disease

Start: 2017-11-06End: 2026-04-17Updated: 2026-05-15

rVWF IN PROPHYLAXIS

CompletedNCT02973087

TakedaVon Willebrand Disease

Start: 2017-11-16End: 2020-07-06Updated: 2021-08-06

Related Papers

A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery

Blood2025-11-03

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study

Blood2025-11-03

Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective

Blood2025-11-03

FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection

Blood2024-11-05

Exposure–Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD

TH Open2024-04-011 citations

von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease

Blood Advances2024-01-1817 citations

An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.

2023-03-021 citations

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Blood2022-04-1932 citations

Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)

Blood2021-11-051 citations